Campath (alemtuzumab) / Bayer, Sanofi 
Welcome,         Profile    Billing    Logout  

76 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Campath (alemtuzumab) / Sanofi
2008-003012-35: CLARET: CLL Levels following Alemtuzumab in Responders to Early Therapy: A randomised, phase III trial to assess alemtuzumab consolidation therapy in patients with chronic lymphocytic leukaemia (CLL) who have responded to previous therapy.

Ongoing
4
116
Europe
Alemtuzumab (MabCampath), Concentrate for solution for injection, Concentrate for solution for infusion, MabCampath
Leeds Teaching Hospitals NHS Trust
Chronic lymphocytic leukaemia (CLL).
 
 
2006-000830-11: A randomised prospective trial of tacrolimus-based steroid avoidance in renal transplantation with either alemtuzumab induction or, basiliximab induction and mycophenolate mofetil maintenance therapy

 
4
120
Europe
MabCampath, Simulect, CellCept, MabCampath, Simulect, CellCept, MabCampath, Simulect, CellCept
Leeds Teaching Hospitals NHS Trust
MabCampath / Alemtuzumab will be used as part of the immunosuppression regime following renal transplant.
 
 
2006-000741-19: A phase I study of subcutaneous alemtuzumab in combination with oral fludarabine in previously untreated patients with chronic lymphocytic leukaemia.

Ongoing
4
20
Europe
MabCampath, Fludarabine, MabCampath, Fludara, MabCampath, Fludara
UHL NHS Trust
Chronic Lymphocytic Leukaemia (CLL)
 
 
2017-003593-13: UK CLL Long Term Follow Up Study

Ongoing
4
800
Europe
Obinutuzumab, Fludarabine, Fludarabine (IV), Cyclophospamide (oral), Cyclophosphamide (IV), Rituximab, Bendamustine, Mitoxantrone, Alemtuzumab, Ofatumumab, Concentrate for solution for infusion, Film-coated tablet, Powder for solution for infusion, Tablet, Powder for concentrate for solution for infusion, Concentrate and solvent for solution for infusion, Obinutuzumab, Fludarabine (oral), Ofatumumab
University of Leeds, Napp Pharmaceuticals
Chronic lymphocytic leukaemia (CLL), Chronic lymphocytic leukaemia (CLL), Diseases [C] - Cancer [C04]
 
 
2018-001680-24: A low-dose immunosuppression protocol in lung transplantation Ein Protokoll mit niedrig dosierte Immunosuppression nach Lungen-Transplantation: eine prospetive randomisierte Studie

Ongoing
4
110
Europe
Prolonged-release tablet, Tablet
Medical University of Vienna - Abteilung für Thoraxchirurgie, Medical University of Vienna
Lung Transplantation, Lung Transplantation, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]
 
 
ACTRN12610000837022: Efficacy and Safety of Alemtuzumab for prevention of graft rejection and preservation of renal function in patients receiving Kidney Transplant

Active, not recruiting
3
63
 
National University Hospital, National Medical Research Council, Singhealth Pivotal Trials Grant
End stage kidney failure
 
 
2005-000309-75: HOVON 68 CLL: A randomized phase III study in prevously untreated patients with biological high risk CLL: Fludarabine + cyclophosphamide (FC) versus FC + low-dose alemtuzumab.

Ongoing
3
80
Europe
MabCampath, Fludara, cyclophosphamide, MabCampath, Fludara, Sendoxan, MabCampath, Fludara, Sendoxan
Christian Geisler, Rigshospitalet, dept. Haematology 4042, Christian Geisler, Righospitalet, dept. Haematology 4042, HOVON CLL Group
Chronic lymphocytic leukaemia (CLL) in biological high-risk group: Unmutated and/or with deletion 17p and/or deletion 11q and/or trisomy 12.
 
 
2006-005275-18: Therapy-optimizing pilot study to investigate the efficacy and safety of an induction therapy with Campath-1H in combination with Tacrolimus for prevention of acute and chronic rejection in patients after primary orthotopic heart transplantation

Ongoing
3
10
Europe
MabCampath, Prograf, Alemtuzumab, Tacrolimus, MabCampath, Prograf, MabCampath, Prograf
Astellas
Therapy-optimizing pilot study to investigate the efficacy and safety of an induction therapy with Campath-1H in combination with Tacrolimus for prevention of acute and chronic rejection in patients after primary orthotopic heart transplantation.
 
 
2019-001770-29: Viral load guided Immunosuppression after Lung Transplantation Viruslast gesteuerte Immunsuppression nach Lungentransplantation

Not yet recruiting
3
144
Europe
Philipps-Universität Marburg, Deutsche Forschungsgemeinschaft (DFG)
Prophylaxis against lung transplant rejectionClinical experience suggests that individual tailoring of immunosuppression for patients after lung transplantation could potentially optimize patient outcome., Prophylaxis against lung transplant rejection
 
 
NCT01897688: A Phase 3 Single Center Study of Islet Transplantation in Non-uremic Diabetic Patients

Active, not recruiting
3
40
US
Islet Cell Transplant
Northwestern University
Type 1 Diabetes, Severe Hypoglycemic Unawareness
03/25
03/27
NCT01361711: Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia

Active, not recruiting
2
53
Europe, US
alemtuzumab, anti-CD52 monoclonal antibody, Campath-1H, MoAb CD52, Monoclonal Antibody Campath-1H, Monoclonal Antibody CD52, ofatumumab, Arzerra, HuMax-CD20, biopsy, biopsies
Northwestern University, GlaxoSmithKline, National Comprehensive Cancer Network
Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
08/15
05/27
2008-006491-30: Etude prospective, multicentrique, de phase II testant la faisabilité d’un traitement d’entretien par l’alemtuzumab chez des patients porteurs de leucémie lymphoïde chronique, traités et répondant à l’alemtuzumab

Ongoing
2
24
Europe
MabCampath, MabCampath, MabCampath
Centre Henri Becquerel
Chronic lymphoid leukemia in complete remission (CR) or partial remission (PR)
 
 
2008-004955-31: Phase II Study of Reduced Intensity Sibling Allogeneic Transplantation for Relapsed, Chemosensitive, PET Positive Hodgkin Lymphoma.Key words: Reduced intensity conditioning, Transplantation, Hodgkin lymphoma

Ongoing
2
49
Europe
Fludarabine, Melphalan, Alemtuzumab,
University College London
Relapsed Hodgkin Lymphoma
 
 
2012-005538-12: A Randomised Trial of the FLAMSA-BU Conditioning Regimen in Patients with Acute Myeloid Leukaemia and Myelodysplasia Undergoing Allogeneic Stem Cell Transplantation

Ongoing
2
170
Europe
Alemtuzumab, Fludarabine, Melphalan, Busilvex, Cytarabine, Amsacrine, Thymoglobulin, Alemtuzumab, Fludarabine, Melphalan, Busulphan, Cytarabine, Amsacrine, Anti-thymocyte Globulin (Rabbit), Campath, Busilvex, Thymoglobulin, Campath, Busilvex, Thymoglobulin
University of Birmingham, Leukaemia and Lymphoma Research, Pierre Fabre
Acute Myeloid Leukaemia (AML) and Myelodysplasia (MDS)
 
 
2010-024389-23: A Phase 2 Trial of Alemtuzumab-Ofatumumab Combination in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia

Ongoing
2
30
Europe
Ofatumumab, MabCampath®, GSK1841157, Arzerra, MabCampath®, Arzerra, MabCampath®
Department of Hematology, GlaxoSmithKlineAB
Chronic Lymphocytic Leukemia
 
 
STRIDE2, NCT02766465: Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)

Completed
2
138
US
Busulfan, Busulfex, Fludarabine, Fludara, r-ATG, Rabbit antithymocyte globulin, Hematopoietic Cell Transplant, Bone Marrow Transplant; BMT; HCT, Tacrolimus, Prograf®, Methotrexate, MTX, Standard of Care, Alemtuzumab, Lemtrada, Total Body Irradiation (TBI), Sirolimus, Rapamune, Melphalan, Alkeran, G-CSF, Granulocyte colony-stimulating factor
Medical College of Wisconsin, National Heart, Lung, and Blood Institute (NHLBI), Blood and Marrow Transplant Clinical Trials Network, Dana-Farber Cancer Institute, National Marrow Donor Program, Emory University
Sickle Cell Disease
05/23
05/23
Sickle-MAID, NCT03214354: Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor

Recruiting
2
12
Canada
Alemtuzumab, Campath, Total Body Irradiation, TBI, Sirolimus
University of Calgary
Sickle Cell Disease, Stem Cell Transplant Complications, Red Blood Cell Disorder, Pure Red Cell Aplasia
07/28
07/28
NCT02626715: Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS

Completed
2
22
US
Reduced-Intensity Conditioning Regimen, Campath, Droxia, Fludara, Alkeran, Thiotepa, Myeloablative Conditioning Regimen, Campath, Thiotepa, Fludara, Busulfex
Randy Windreich
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Hematopoietic Stem Cell Transplant (HSCT)
04/23
04/23
NCT00408447: Stem Cell Transplant in Sickle Cell Disease and Thalassemia

Active, not recruiting
2
53
US
Busulfan, Busulfex, Fludarabine, Fludara, Alemtuzumab, Campath, Allogeneic stem cell transplant, Related Bone Marrow, Related Cord Blood
Columbia University
Sickle Cell Disease, Beta Thalassemia
02/25
02/25
NCT02105766: Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure

Recruiting
2
162
US
Alemtuzumab, Sirolimus, Cyclophosphamide, Pentostatin, Radiotherapy
National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI), National Institutes of Health Clinical Center (CC)
Sickle Cell Disease, Thalassemia, Stem Cell Transplantation, Graft vs Host Disease
12/23
12/24
NCT04312841: Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

Active, not recruiting
2
6
US
Letermovir, 2-((4S)-8-Fluoro-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3-(2-methoxy-5-(trifluoromethyl)phenyl)-4H-quinazolin-4-yl)acetic Acid, AIC246, MK-8228, Prevymis
Ohio State University Comprehensive Cancer Center, Merck Sharp & Dohme LLC
B-Cell Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia, Peripheral T-Cell Lymphoma, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome, T-Cell Prolymphocytic Leukemia
04/24
12/24
NCT01659606: Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita

Active, not recruiting
2
40
Europe, US
alemtuzumab, Campath-1H, Fludarabine, Fludara, Cyclosporins, cyclosporine A, Neoral, Sandimmune, Mycophenolate mofetil, Cellcept, Tacrolimus, FK506, Prograf
Boston Children's Hospital, Dana-Farber Cancer Institute, Children's Hospital Medical Center, Cincinnati, Children's Hospital Los Angeles, Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Baylor College of Medicine, Children's Hospital of Philadelphia, University of Wisconsin, Madison, Karolinska University Hospital, Hackensack Meridian Health, Duke University, Oslo University Hospital, Children's Mercy Hospital Kansas City, Mayo Clinic, University of Chicago, Massachusetts General Hospital
Dyskeratosis Congenita, Hoyeraal Hreidarsson Syndrome, Revesz Syndrome, Aplastic Anemia
04/24
12/34
SUN-RAY, NCT06358638: Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell AntibodY

Recruiting
2
12
US
Daratumumab, Darzalex, Alemtuzumab, Campath-1H, Sirolimus, Rapamune, Total Body Irradiation, TBI
Children's National Research Institute, Alberta Children's Hospital, The Hospital for Sick Children, Levine Children's Hospital, Ann & Robert H Lurie Children's Hospital of Chicago, Nationwide Children's Hospital, Children's Hospital at Montefiore, Doris Duke Charitable Foundation, Janssen Pharmaceuticals
Sickle Cell Disease
09/44
09/54
NCT04362293: Reduced Intensity Transplantation for Severe Sickle Cell Disease

Suspended
2
40
US
hydroxyurea, azathioprine, alemtuzumab, thioptepa, low dose total body irradiation and sirolimus, hydroxyurea, azathioprine, alemtuzumab, thiotepa, plerixafor, low dose total body irradiation, cyclophosphamide and sirolimus
St. Jude Children's Research Hospital
Sickle Cell Disease
07/24
07/25
NCT03630211: Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis

Recruiting
2
8
US
Cyclophosphamide, Mesna, Rituximab, Rituxan, Alemtuzumab, Campath-1H, Thiotepa, GM-CSF, Neupogen, Filgrastim, Intravenous immunoglobulin, Total Body Irradiation, Anti Thymocyte Globulin, Thymoglobulin
Paul Szabolcs
Systemic Sclerosis, Diffuse Sclerosis Systemic, Interstitial Lung Disease, Pulmonary Hypertension
08/24
08/25
NCT01962415: Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

Recruiting
2
100
US
Hydroxyurea, hydroxycarbamide, Hydrea, Droxia, Alemtuzumab, Campath, Fludarabine, Fludara, Melphalan, Melphalan hydrochloride, Alkeran, Thiotepa
Paul Szabolcs
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions, Systemic Juvenile Idiopathic Arthritis (sJIA)
11/24
11/24
ALL-RIC, NCT03821610 / 2017-004800-23: A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission.

Active, not recruiting
2
242
Europe
Fludarabine, Melphalan, Alemtuzumab, Cyclophosphamide, Mesna, Total Body Irradiation (8Gy)
University of Birmingham
Acute Lymphoblastic Leukemia
11/24
11/27
SUN, NCT03587272: Minimizing Toxicity in HLA-identical Related Donor Transplantation for Children With Sickle Cell Disease

Recruiting
2
30
Canada, US
Alemtuzumab, low dose total body irradiation, Sirolimus
Robert Nickel, Alberta Children's Hospital, The Hospital for Sick Children, Levine Children's Hospital, Ann & Robert H Lurie Children's Hospital of Chicago, Nationwide Children's Hospital, The Children's Hospital at Montefiore, Morgan Stanley Children's Hospital
Sickle Cell Disease
11/25
11/25
NCT04232085: Reduced Intensity BMT for Immune Dysregulatory and Bone Marrow Failure Syndromes Using Post-Transplant Cyclophosphamide

Recruiting
2
27
US
Alemtuzumab, Campath, Fludarabine, Melphalan, Low Dose Total Body Irradiation, Cyclophosphamide, Cytoxan, Tacrolimus, FK506, Prograf, Mycophenolate Mofetil, MMF, Cellcept
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Primary Immune Deficiency Disorder, Immune Deficiency Disease, Bone Marrow Failure
12/24
12/26
UPFRONT-MUD, NCT05419843: Up-front Matched Unrelated Donor Transplantation in Pediatric Patients With Idiopathic Aplastic Anemia

Not yet recruiting
2
25
NA
HSCT Arm group
Assistance Publique - Hôpitaux de Paris
Idiopathic Aplastic Anemia, Severe Aplastic Anemia, Moderate Aplastic Anemia Requiring Transfusions
08/25
06/27
NCT01909245: Islet Cell Transplant for Type 1 Diabetes

Active, not recruiting
2
10
US
Allogenic Human Islet Cells, Islet transplant, islet transplantation, Immunosuppressive Agents, Gastrin 17, GAST-17
City of Hope Medical Center, University of California, Los Angeles
Type 1 Diabetes Mellitus
10/25
10/25
NCT01050855: Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders

Active, not recruiting
2
75
US
RIC: Distal Campath, Reduced Intensity Conditioning Regimen, RIC:Intermediate Campath, RIC: Mini Busulfan
Children's Hospital of Philadelphia
Non Malignant Diseases, Immunodeficiencies, Hemoglobinopathies
12/25
12/26
TRANSCAPE, NCT06084780: Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei

Not yet recruiting
2
20
US
Intestinal, Multivisceral or Modified Multivisceral Transplantation, Alemtuzumab, Tacrolimus, Sirolimus
Case Comprehensive Cancer Center
Secondary Malignant Neoplasm of Retroperitoneum, Secondary Malignant Neoplasm of Peritoneum, Pseudomyxoma Peritonei
12/25
12/25
NCT03579875: Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders

Recruiting
2
48
US
Total Body Irradiation (TBI) (Plan 1), TBI, Cyclophosphamide (CY) (Plan 1), CY, Fludarabine (FLU), FLU, Methylprednisolone (MP), MP, Donor mobilized PBSC infusion, PBSC, G-CSF, Cyclophosphamide (CY) (Plan 2), Rituximab, Busulfan, BU, Alemtuzumab, Melphalan, MEL
Masonic Cancer Center, University of Minnesota
Fanconi Anemia, Severe Aplastic Anemia, Myelodysplastic Syndromes, T Cell Receptor Alpha/Beta Depletion, Telomere Biology Disorder, Bone Marrow Failure, Dyskeratosis Congenita
01/26
01/29
NCT04339777: Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity

Recruiting
2
66
US
Busulfan test dose, Fludarabine, Busulfan, Alemtuzumab, Total body Irradiation, Allogeneic HSCT, Tacrolimus (Tacro), Mycophenolate mofetil (MMF), Cyclophosphamide (Cytoxan)
National Cancer Institute (NCI)
Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Immune System Diseases, Common Variable Immunodeficiency, Primary T-cell Immunodeficiency Disorders
10/26
11/27
NCT04018937: Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation

Recruiting
2
58
Canada, US
Alemtuzumab, Campath, Fludarabine, Fludara, Melphalan, Alkeran, Evomela
Emory University
Sickle Cell Disease
01/27
01/27
NCT01821781: Immune Disorder HSCT Protocol

Recruiting
2
20
US
Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
Washington University School of Medicine
Immune Deficiency Disorders, Severe Combined Immunodeficiency, Chronic Granulomatous Disease, X-linked Agammaglobulinemia, Wiskott-Aldrich Syndrome, Hyper-IgM, DiGeorge Syndrome, Chediak-Higashi Syndrome, Common Variable Immune Deficiency, Immune Dysregulatory Disorders, Hemophagocytic Lymphohistiocytosis, IPEX, Autoimmune Lymphoproliferative Syndrome, X-linked Lymphoproliferative Syndrome
03/27
03/27
NCT05501756: Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation

Recruiting
2
60
US
Alemtuzumab, Campath
Children's Hospital Medical Center, Cincinnati
Allogeneic Hematopoietic Cell Transplantation
08/28
08/28
NCT00924170: Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia

Completed
1/2
18
US
LMB-2, Fludarabine, Fludara, Cyclophosphamide, Cytoxan
National Cancer Institute (NCI)
Adult T-Cell Leukemia (ATL)
01/16
05/21
BendAlem, 2008-004987-37`ACTRN12610000060044: Bendamustine Combined with Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL) – A Phase I/II Trial with Concomitant Evaluation of Safety and Efficacy

Completed
1/2
20
Europe
Bendamustin, Ribomustin, Ribomustin
Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH, Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH
Chronic Lymphocytic Leukaemia (CLL)
 
08/12
NCT00977691: Haploidentical PBMC Transplant for Severe Congenital Anemias

Active, not recruiting
1/2
23
US
PBSC Transplant, Alemtuzumab, Campath, Sirolimus, Rapamune, Cyclophosphamide, Cytoxan, Low Dose Irradiation
National Heart, Lung, and Blood Institute (NHLBI)
Sickle Cell Anemia
08/18
09/26
NCT02061800: CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

Active, not recruiting
1/2
14
US
CliniMACS CD34+ Reagent System, Thiotepa, Thioplex, Cyclophosphamide, Cytoxan, Alemtuzumab, Campath, Tacrolimus, Prograf, FK506, Melphalan, Alkeran, Busulfan, Busulfex, Fludarabine, Fludara, Methylprednisolone, Solu-Medrol
Diane George
Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Juvenile Myelomonocytic Leukemia (JMML), Acute Lymphoblastic Leukemia (ALL), Lymphoma (Hodgkin's and Non-Hodgkin's)
07/26
07/26
NCT00061568: Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias

Active, not recruiting
1/2
130
US
Peripheral blood hematopoietic progenitor cell (PBPC) transplant, Alemtuzumab, Campath, Peripheral blood hematopoietic progenitor cell Apheresis, Sirolimus, Rapamune
National Heart, Lung, and Blood Institute (NHLBI)
Congenital Hemolytic Anemia, Sickle Cell Disease
01/23
01/26
NCT03077542: Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease

Active, not recruiting
1/2
55
US
haploidentical stem cell transplant, sirolimus, campath, pentostatin, cyclophosphamide, Hydroxyurea
National Heart, Lung, and Blood Institute (NHLBI)
Sickle Cell Disease
07/23
08/26
NCT03500731: Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure

Recruiting
1/2
8
US
CD3/CD19 negative hematopoietic stem cells, Rituximab, Rituxan, Alemtuzumab, Campath-1H, Fludarabine, Fludara, Oforta, Thiotepa, G-CSF, Neupogen, Granix, Zarxio, Filgrastim, Hydroxyurea
Paul Szabolcs
Idiopathic Pulmonary Fibrosis, Emphysema or COPD
12/24
12/26
NCT06145282: Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function

Recruiting
1/2
72
US
Non-myeloablative haploidentical peripheral blood stem cell transplantation with briquilimab and abatacept
National Heart, Lung, and Blood Institute (NHLBI)
Sickle Cell Disease
09/32
03/33
BALLI-01, NCT04150497: Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia

Recruiting
1/2
40
Europe, US
UCART22, CLLS52, Alemtuzumab
Cellectis S.A.
B-cell Acute Lymphoblastic Leukemia
12/23
01/26
NCT01499888: Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)

Recruiting
1/2
15
US
Allogeneic Non-Myeloablative Stem Cell Transplantation, Alemtuzumab, Campath, MabCampath, Campath-1H, Sirolimus, Rapamune, Rapamycin
University of Illinois at Chicago
Sickle Cell Disease
01/25
05/25
NCT03128996: Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

Recruiting
1/2
29
US
RIC regimen, Transplant Preparative Regimen, Transplant Conditioning Regimen, GVHD prophylaxis regimen, Graft versus Host Disease prophylaxis regimen
Washington University School of Medicine
Severe Sickle Cell Disease, Bone Marrow Failure Syndromes, Metabolic Disorders, Immunologic Disorders, Hemoglobinopathies, Non-malignant Disorders
04/24
04/26
NCT03182426: Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)

Active, not recruiting
1/2
60
Canada
Plerixafor, Mozobil, Alemtuzumab, Lemtrada, Anakinra, Kineret, Etanercept, Enbrel, Liraglutide, Victoza
University of Alberta, Alberta Innovates Health Solutions
Diabetes Mellitus, Type 1
07/24
12/25
NCT03653338: T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias

Recruiting
1/2
5
US
CD3/CD19 depleted leukocytes, CD45RA depleted leukocytes, Hydroxyurea, HU, Hydrea, Rituximab, Rituxan, Alemtuzumab, Campath-1H, Fludarabine, Fludara, Thiotepa
Paul Szabolcs
Sickle Cell Anemia, Beta-thalassemia Major, Diamond-blackfan Anemia
08/24
08/26
NCT00692939: Autologous Stem Cell Transplantation for Crohn's Disease

Recruiting
1/2
20
US
autologous CD34-selected peripheral blood stem cells transplant, Alemtuzumab, Campath-1H, ATG, Anti-thymocyte globulin, rabbit; Thymoglobulin, Melphalan, L-phenylalanine mustard, phenylalanine mustard, L-PAM, or L-sarcolysin, Thiotepa, Rituximab, Rituxan, Cyclophosphamide, Cytoxan, G-CSF, Neupogen, Granix, Zarxio, Filgrastim, Mesna
Paul Szabolcs
Crohn's Disease
12/25
12/26
NCT02629120: High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease

Active, not recruiting
1/2
44
US
Alemtuzumab, Busulfan, Sirolimus, Cyclophosphamide, Total Body Irradiation, Peripheral blood stem cells
National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Granulomatous Disease Transplant
11/26
11/26
NCT00920972: Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases

Recruiting
1/2
220
Canada, US
Treatment Plan 1: Stratum 1, Treatment Plan 2: Strata 2, 3, or 4, GVHD Regimen A: UCB Recipients, GVHD Regimen B: BM Recipients
Washington University School of Medicine, St. Louis Children's Hospital
Metabolic Disorders, Hematologic, Immune, or Bone Marrow Disorders, Hemoglobinopathies, Non-malignant Disorders
12/26
12/31
NatHaLi-01, NCT05607420: Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma

Recruiting
1/2
80
Europe, US
UCART20x22, CLLS52, Alemtuzumab
Cellectis S.A.
B-cell Non-Hodgkin Lymphoma (B-NHL)
11/27
11/27
NCT05357482: Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia

Recruiting
1/2
90
US
TBI, Hydroxyurea, briquilimab, Filgrastim (G-CSF), Sirolimus, Alemtuzumab, Plerixafor
National Heart, Lung, and Blood Institute (NHLBI)
Sickle Cell Anemia, Beta Thalassemia
11/32
11/33
NCT05463133: Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists

Recruiting
1/2
50
US
Sirolimus, Cyclophosphamide, Alemtuzumab, Busulfan, Pheripheral blood stem cells, Emapalumab-Izsg, Tociluzumab, Total Body Irradiation
National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Granulomatous Disease
12/32
12/32
NCT02867800: Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease

Completed
1
24
US
Diphenhydramine, Benadryl, Acetaminophen, Tylenol, Methylprednisolone, Medrol, Meperidine, Demerol, Alemtuzumab, Lemtrada, Thymoglobulin, Genzyme, Fludarabine, Fludara, Melphalan, Alkeran, Thiotepa, Thioplex, Cyclosporine, Neoral, Tacrolimus, Protopic, Methotrexate, Trexall, Abatacept, CTLA4-Ig, Orencia, Marrow infusion, stem cell transplant, Sirolimus, Rapamune, Mycophenolate Mofetil, MMF
Monica Bhatia
Sickle Cell Disease, Graft Versus Host Disease
12/21
12/23
NCT03444064: PolyTreg Immunotherapy in Islet Transplantation

Active, not recruiting
1
18
Canada
PolyTregs, Ex vivo Expanded Autologous CD4+CD127lo/-CD25+ Polyclonal Regulatory T cells
University of Alberta, Diabetes Research Institute Foundation, Liana's Dream Foundation, Juvenile Diabetes Research Foundation, Alberta Diabetes Institute
Diabetes, Diabetes Mellitus, Type 1
08/22
05/24
NCI-2019-03203, NCT03989466: Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia

Active, not recruiting
1
15
US
Alemtuzumab, Anti-CD52 Monoclonal Antibody, Campath, Campath-1H, LDP-03, Lemtrada, MabCampath, Monoclonal Antibody Campath-1H, Itacitinib, INCB 039110, INCB-039110, INCB039110
M.D. Anderson Cancer Center
Recurrent T-Cell Prolymphocytic Leukemia, T-Cell Prolymphocytic Leukemia
12/26
12/26
aGVHD，hAESCs, NCT06164288: Safety and Efficacy Study of hAESCs Therapy for aGVHD

Not yet recruiting
1
18
NA
Human Amniotic Epithelial Stem Cell Injection
Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
GVHD,Acute
12/24
06/25
TEACH, NCT03504241: Tolerance by Engaging Antigen During Cellular Homeostasis

Active, not recruiting
1
8
US
Donor-derived Mesenchymal Stromal Cells, Donor-derived MSCs, human bone marrow derived MSCs, hBM-MSC, EPIC-MSC-ITN2015-IVF-0X, alemtuzumab, Campath®, Lemtrada®, belatacept, Nulojix®, LEA29Y, sirolimus, Rapamune®, mycophenolate mofetil, CellCept®, mycophenolate acid, Myfortic®, prednisone, corticosteroid
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), PPD, Rho Federal Systems Division, Inc.
Kidney Transplantation, Renal Transplantation, Renal Transplant Recipient
12/27
12/29
NCI-2022-03571, NCT05384756: TMLI and Alemtuzumab for Treatment of Sickle Cell Disease

Recruiting
1
20
US
Alemtuzumab, Anti-CD52 Monoclonal Antibody, Campath, Campath-1H, LDP-03, Lemtrada, MabCampath, Monoclonal Antibody Campath-1H, Hematopoietic Cell Transplantation, HCT, Hematopoietic Stem Cell Infusion, Hematopoietic Stem Cell Transplantation, HSCT, Stem Cell Transplant, stem cell transplantation, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Sirolimus, AY 22989, RAPA, Rapamune, Rapamycin, SILA 9268A, WY-090217
City of Hope Medical Center, National Cancer Institute (NCI)
Sickle Cell Disease
12/26
12/26
NCT03910452: Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide

Recruiting
1
30
US
Busulfan, Alemtuzumab, Cyclophosphamide, Sirolimus, Total Body Irradiation, Allogeneic peripheral blood stem cell
National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Granulomatous Disease
06/34
06/34
NCT00647010: T-cell Recovery in Patients With Leukemia, Advanced Lymphoma, Myelodysplastic Syndrome, or Myeloproliferative Disorder Receiving Alemtuzumab and Undergoing Donor Stem Cell Transplant

Recruiting
N/A
40
US
alemtuzumab, cyclophosphamide, cytarabine, laboratory biomarker analysis, allogeneic hematopoietic stem cell transplantation, total-body irradiation
Baylor College of Medicine
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
12/12
 
NCT00619528: HLA-Identical Sibling Renal Transplant Tolerance

Active, not recruiting
N/A
230
US
Infusion of Donor Hematopoietic Stem Cells and Campath-1H
Northwestern University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Immunosuppression, Kidney Transplantation, Graft Rejection
07/22
06/23
NCT04436380: Retrospective Study of Patients With Severe Aplastic Anemia Who Relapsed After Immunosuppressive Therapy

Completed
N/A
173
US
National Heart, Lung, and Blood Institute (NHLBI)
Severe Aplastic Anemia
03/23
03/23
T-PLL, NCT04411043: Observatory of Prolymphocytic Leukemia T

Recruiting
N/A
50
Europe
Molecular caracterization
French Innovative Leukemia Organisation, University Hospital, Lille
Prolymphocytic Leukemia, T-cell Leukemia
06/23
06/25
NCT05249452: Adding Azathioprine/Hydroxyurea Preconditioning to Alemtuzumab/TBI to Reduce Risk of Graft Failure in MSD HSCT in Adult SCD Patients

Recruiting
N/A
20
Europe
Preconditioning with azathiprine and hydroxyurea (3 months)
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Sickle Cell Disease
08/23
12/23
PROTECT, NCT05200338: Preservation and Transfer of HBV Immunity After Allogeneic HSCT for SCD

Recruiting
N/A
30
Europe
Engerix-B
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Sickle Cell Disease
01/24
12/24
NCT02162420: Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia

Recruiting
N/A
50
US
Alemtuzumab, Fludarabine, Fludara, Cyclophosphamide, Total Body Irradiation, TBI, Stem Cell Transplant, HSCT, Anti-thymocyte globulin, Rabbit ATG
Masonic Cancer Center, University of Minnesota
Dyskeratosis Congenita, Aplastic Anemia
07/25
07/26
PREDICT, NCT05905770: Do Alemtuzumab Levels Predict T Cell Chimerism After MSD SCT for SCD?

Recruiting
N/A
20
Europe
Alemtuzumab Injection [Campath]
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Leiden University Medical Center
Sickle Cell Disease
11/24
11/25
NCT01652092: Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

Recruiting
N/A
30
US
Alemtuzumab 0.3 mg, Campath-1H, Cyclophosphamide, Cytoxan, Busulfan, Myerlan, Stem Cell Transplantation, Fludarabine phosphate 40 mg, Fludara, Melphalan, Alkeran, Alemtuzumab 0.2 mg, Campath 1-H, Fludarabine phosphate 30 mg, MESNA, mercaptoethane sulfonate Na (Na being the symbol for sodium), Mesnex
Masonic Cancer Center, University of Minnesota
SCID, Omenn's Syndrome, Reticular Dysgenesis, Wiskott-Aldrich Syndrome, Bare Lymphocyte Syndrome, Common Variable Immunodeficiency, Chronic Granulomatous Disease, CD40 Ligand Deficiency, Hyper IgM Syndrome, X-linked Lymphoproliferative Disease, Hemophagocytic Lymphohistiocytosis, Griscelli Syndrome, Chediak-Higashi Syndrome, Langerhan's Cell Histiocytosis
12/25
12/26
ROSETTE, NCT06100965: Reduced-dose Alemtuzumab for Kidney Transplant Rejection

Recruiting
N/A
25
Europe
Erasmus Medical Center
Kidney Transplant Rejection
07/25
07/26
VGILung, NCT04198506: Viral Load Guided Immunosuppression After Lung Transplantation

Active, not recruiting
N/A
144
Europe
Tailored tacrolimus dosing, Conventional tacrolimus dosing
Philipps University Marburg Medical Center
Transplantation Lung
12/25
12/25
PRO-RIC, NCT04528355: Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC

Recruiting
N/A
50
US
data collection
Paul Szabolcs
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions
12/25
06/26

Download Options